Janssen antibody could be lung cancer breakthrough

The FDA thinks a dual-target antibody from Janssen could set new standards in treatment for certain patients with lung cancer, whose disease has progressed after chemotherapy and are unlike

China backs Roche's Actemra to fight coronavirus complicatio...

Chinese authorities have issued guidelines recommending Roche’s anti-inflammation drug Actemra to combat severe complications caused by the COVID-19 coronavirus.

AbbVie/Roche's Venclexta fails in confirmatory AML trial

AbbVie and Roche's Venclexta has failed to significantly improve overall survival in an acute myeloid leukaemia (AML) trial that was supposed to confirm its efficacy.

NICE rejects Roche's Polivy combination in advanced lymphoma

England’s NHS should not fund Roche’s Polivy (polatuzumab vedotin) in combination with rituximab and bendamustine for adults with a form of advanced lymphoma, NICE has said in first draft g

Roche hops on Bicycle’s drug discovery platform for cancer

US, EU reviews start for Novartis’ Ocrevus rival ofatumumab